Yu Ding

1.8k total citations · 1 hit paper
34 papers, 1.1k citations indexed

About

Yu Ding is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yu Ding has authored 34 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Yu Ding's work include Cancer Immunotherapy and Biomarkers (8 papers), Allergic Rhinitis and Sensitization (6 papers) and Asthma and respiratory diseases (4 papers). Yu Ding is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Allergic Rhinitis and Sensitization (6 papers) and Asthma and respiratory diseases (4 papers). Yu Ding collaborates with scholars based in China, United States and Germany. Yu Ding's co-authors include Vassiliki Karantza, Peter Schmid, David W. Cescon, Hirofumi Mukai, Hiroji Iwata, Sherene Loi, Michelino De Laurentiis, Rita Nanda, Anne Armstrong and Eric P. Winer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Yu Ding

30 papers receiving 1.1k citations

Hit Papers

Pembrolizumab monotherapy for previously untreated, PD-L1... 2018 2026 2020 2023 2018 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
    2018 460 citations Sylvia Adams, Sherene Loi et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yu Ding China 14 670 282 260 259 228 34 1.1k
Qiongyu Hao United States 15 218 0.3× 153 0.5× 220 0.8× 81 0.3× 424 1.9× 28 789
Wendy W. Dye United States 15 378 0.6× 52 0.2× 216 0.8× 188 0.7× 345 1.5× 24 1.0k
Jian Pang China 15 182 0.3× 132 0.5× 194 0.7× 104 0.4× 341 1.5× 34 700
Pattatheyil Arun India 17 337 0.5× 121 0.4× 289 1.1× 97 0.4× 457 2.0× 50 947
Zhaohui Chen China 17 327 0.5× 232 0.8× 349 1.3× 208 0.8× 712 3.1× 55 1.3k
Pravin Kesarwani United States 21 266 0.4× 390 1.4× 291 1.1× 101 0.4× 477 2.1× 44 1.1k
Lei Zhan China 23 164 0.2× 212 0.8× 460 1.8× 138 0.5× 704 3.1× 55 1.4k
Jinqi Xue China 14 232 0.3× 120 0.4× 202 0.8× 91 0.4× 441 1.9× 30 796
Caroline Perry United States 15 257 0.4× 171 0.6× 164 0.6× 87 0.3× 526 2.3× 25 1.1k
Yoo Jin Na South Korea 20 207 0.3× 84 0.3× 177 0.7× 91 0.4× 476 2.1× 37 900

Countries citing papers authored by Yu Ding

Since Specialization
Citations

This map shows the geographic impact of Yu Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Ding more than expected).

Fields of papers citing papers by Yu Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Ding. The network helps show where Yu Ding may publish in the future.

Co-authorship network of co-authors of Yu Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Ding. A scholar is included among the top collaborators of Yu Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Ding. Yu Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ding, Yu, et al.. (2025). Heterogeneous Copper Single‐Atom Catalyzed Three‐Component Radical Difunctionalization of Alkenes. Advanced Synthesis & Catalysis. 368(2).
2.
Wang, Haiyu, et al.. (2025). Application and progress of nomograms in gastric cancer. Frontiers in Medicine. 12. 1510742–1510742. 1 indexed citations
3.
Chen, Lei, Feng Feng, Tiehui Fang, et al.. (2025). Nano Copper‐chelate Triggers Cuproptosis‐like Death in Fungi and Synergizes with Microneedles for Enhanced Biofilm Removal. Advanced Healthcare Materials. 14(10). e2404464–e2404464. 3 indexed citations
4.
5.
6.
Wang, Haiyu, et al.. (2024). Establishment and validation of a nomogram model for early diagnosis of gastric cancer: a large-scale cohort study. Frontiers in Oncology. 14. 1463480–1463480. 2 indexed citations
7.
8.
Schmid, Peter, Javier Cortés, Rebecca Dent, et al.. (2023). LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. Annals of Oncology. 34. S1257–S1257. 20 indexed citations
9.
10.
Lu, Yiran, Ruiqing Wang, Song He, et al.. (2023). Downregulation of BUBR1 regulates the proliferation and cell cycle of breast cancer cells and increases the sensitivity of cells to cisplatin. In Vitro Cellular & Developmental Biology - Animal. 59(10). 778–789. 2 indexed citations
11.
Wang, Chen, Yu Ding, Yuanyong Liu, et al.. (2020). Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation. Frontiers in Immunology. 11. 576603–576603. 7 indexed citations
12.
Zhang, Shun, et al.. (2020). Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate Cancer. Chemotherapy. 65(5-6). 125–133. 8 indexed citations
13.
Tao, Shu, Zhen Zhao, Xin‐Yuan Guan, et al.. (2020). The role of macrophages during breast cancer development and response to chemotherapy. Clinical & Translational Oncology. 22(11). 1938–1951. 26 indexed citations
14.
Adams, Sylvia, Sherene Loi, Deborah Toppmeyer, et al.. (2018). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Annals of Oncology. 30(3). 405–411. 460 indexed citations breakdown →
15.
Adams, Sylvia, Sherene Loi, Deborah Toppmeyer, et al.. (2017). Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. Journal of Clinical Oncology. 35(15_suppl). 1088–1088. 55 indexed citations
16.
Li, Chuanfeng, et al.. (2017). Effect of Drying Method on Total Flavonoids in Red Jujube. SHILAP Revista de lepidopterología. 1 indexed citations
17.
Yan, Yutao, Yu Ding, Bingxia Ming, et al.. (2014). Increase in Hypotonic Stress-Induced Endocytic Activity in Macrophages via ClC-3. Molecules and Cells. 37(5). 418–425. 13 indexed citations
18.
Storms, William W., Nathan Segall, Lyndon E. Mansfield, et al.. (2013). Efficacy and safety of beclomethasone dipropionate nasal aerosol in pediatric patients with seasonal allergic rhinitis. Annals of Allergy Asthma & Immunology. 111(5). 408–414.e1. 18 indexed citations
19.
Peterson, Barry T., Ping Chiao, Eve H. Pickering, et al.. (2012). Comparison of actigraphy and polysomnography to assess effects of zolpidem in a clinical research unit. Sleep Medicine. 13(4). 419–424. 34 indexed citations
20.
Huang, Mou‐Tuan, et al.. (2000). Anti‐tumor and anti‐carcinogenic activities of triterpenoid, β‐boswellic acid. BioFactors. 13(1-4). 225–230. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qiongyu Hao Breakdown of academic impact, for papers by Wendy W. Dye Breakdown of academic impact, for papers by Jian Pang Breakdown of academic impact, for papers by Pattatheyil Arun Breakdown of academic impact, for papers by Zhaohui Chen Breakdown of academic impact, for papers by Pravin Kesarwani Breakdown of academic impact, for papers by Lei Zhan Breakdown of academic impact, for papers by Jinqi Xue Breakdown of academic impact, for papers by Caroline Perry Breakdown of academic impact, for papers by Yoo Jin Na
Rankless by CCL
2026